Departament de Farmacología, Toxicologia i Quimica Terapéutica, Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain.
Biomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Mol Neurobiol. 2018 Sep;55(9):7327-7339. doi: 10.1007/s12035-018-0868-4. Epub 2018 Feb 5.
There is growing evidence that obesity associated with type 2 diabetes mellitus (T2DM) and aging are risk factors for the development of Alzheimer's disease (AD). However, the molecular mechanisms through which obesity interacts with β-amyloid (Aβ) to promote cognitive decline remains poorly understood. Memantine (MEM), a N-methyl-D-aspartate receptor antagonist, is currently used for the treatment of AD. Nonetheless, few studies have reported its effects on genetic preclinical models of this neurodegenerative disease exacerbated with high-fat diet (HFD)-induced obesity. Therefore, the present research aims to elucidate the effects of MEM on familial AD HFD-induced insulin resistance and learning and memory impairment. Furthermore, it aspires to determine the possible underlying mechanisms that connect AD to T2DM. Wild type and APPswe/PS1dE9 mice were used in this study. The animals were fed with either chow or HFD until 6 months of age, and they were treated with MEM-supplemented water (30 mg/kg) during the last 12 weeks. Our study demonstrates that MEM improves the metabolic consequences produced by HFD in this model of familial AD. Behavioural assessments confirmed that the treatment also improves animals learning abilities and decreases memory loss. Moreover, MEM treatment improves brain insulin signalling upregulating AKT, as well as cyclic adenosine monophosphate response element binding (CREB) expression, and modulates the amyloidogenic pathway, which, in turn, reduced the accumulation of Aβ. Moreover, this drug increases the activation of molecules involved with insulin signalling in the liver, such as insulin receptor substrate 2 (IRS2), which is a key protein regulating hepatic resistance to insulin. These results provide new insight into the role of MEM not only in the occurrence of AD treatment, but also in its potential application on peripheral metabolic disorders where Aβ plays a key role, as is the case of T2DM.
越来越多的证据表明,与 2 型糖尿病(T2DM)和衰老相关的肥胖是阿尔茨海默病(AD)发展的危险因素。然而,肥胖与β-淀粉样蛋白(Aβ)相互作用促进认知能力下降的分子机制仍知之甚少。美金刚(MEM)是一种 N-甲基-D-天冬氨酸受体拮抗剂,目前用于治疗 AD。尽管如此,很少有研究报道其对高脂肪饮食(HFD)诱导肥胖加重的这种神经退行性疾病的遗传临床前模型的影响。因此,本研究旨在阐明 MEM 对家族性 AD HFD 诱导的胰岛素抵抗和学习记忆障碍的影响。此外,它旨在确定将 AD 与 T2DM 联系起来的可能潜在机制。本研究使用野生型和 APPswe/PS1dE9 小鼠。这些动物分别用标准饲料或 HFD 喂养,直到 6 个月大,然后在最后 12 周用含 MEM 的水(30mg/kg)进行治疗。我们的研究表明,MEM 改善了该家族性 AD 模型中 HFD 产生的代谢后果。行为评估证实,该治疗还可改善动物的学习能力并减少记忆丧失。此外,MEM 治疗可改善大脑胰岛素信号,上调 AKT,以及环磷酸腺苷反应元件结合(CREB)的表达,并调节淀粉样蛋白形成途径,从而减少 Aβ的积累。此外,这种药物增加了肝脏中参与胰岛素信号的分子的激活,如胰岛素受体底物 2(IRS2),IRS2 是调节肝脏对胰岛素抵抗的关键蛋白。这些结果不仅为 MEM 在 AD 治疗中的作用提供了新的见解,而且为其在 Aβ发挥关键作用的外周代谢紊乱中的潜在应用提供了新的见解,如 T2DM。